A Phase 4 interventional study of Linagliptin in Diabetes Mellitus, sponsored by Profil Institut für Stoffwechselforschung GmbH. Completed at 1 site in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-03-03.
Sponsored by Profil Institut für Stoffwechselforschung GmbH · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing linagliptin in Diabetes Mellitus — 1 open to participants now, 1 under way, none of them phase 3. Linagliptin · Diabetes Mellitus.
Among the 11 studies testing linagliptin in Diabetes Mellitus, this one is the 4th largest by enrollment, is one of 2 that started in 2013, is one of 8 in phase 4, and was the 2nd registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →1 of the 11 studies testing linagliptin in Diabetes Mellitus is open now, in 1 country. Recruiting first, the newest first:
Nabiqasim Industries (Pvt) Ltd · Sites in Pakistan
Ages 18–80
By country, each count listing its studies:
Linagliptin: first FDA approval 2011 (TRADJENTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 99 is above the median of 80 across 6,025 interventional studies indexed under Diabetes Mellitus.
Median enrollment 48 across the 11 interventional studies. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 11 have an industry lead sponsor. The 10 most frequent:
Profil Institut für Stoffwechselforschung GmbH is the lead sponsor of 26 studies on the registry; 1 is open to participants now.
15 studies in Diabetes Mellitus by Profil Institut für Stoffwechselforschung GmbH: none open now, none under way, none of them phase 3. Of 15 finished, 0 (0%) have results posted.
Among the 15 studies in Diabetes Mellitus by Profil Institut für Stoffwechselforschung GmbH, this one is the 2nd largest by enrollment, is one of 4 that started in 2013, is one of 2 in phase 4, and was the 8th registered.
Profil Institut für Stoffwechselforschung GmbH’s Diabetes Mellitus studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing linagliptin in Diabetes Mellitus, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Profil Institut für Stoffwechselforschung GmbH’s 15 in Diabetes Mellitus:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a bi-centric, prospective, open study comparing the effects of linagliptin on active GLP-1 concentrations in subjects with renal impairment compared to subjects with normal renal function.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Linagliptin in TD2 subjects with normal renal function
Drug: Linagliptin
Linagliptin in TD2 subjects with impaired renal function
Drug: Linagliptin
ΔAUCGLP-1-OGTT(0-240)
ΔAUCGLP-1-OGTT(0-240) Change in active GLP-1 concentrations after oral glucose ingestion after linagliptin Treatment compared between Groups.
Time frame: Glucose tolerance test following 7 days of therapy
Ran from Jul 2013 to primary completion in Apr 2016, 33 months.
Of 48 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 22. This study's 33 months is above that.
Counting every sponsor, half of 197 studies reached it within 24 months; a quarter within 13 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Linagliptin
Profil Institut für Stoffwechselforschung GmbH →